Enzolytics, Inc. is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2. Using a proprietary isolation and optimization methodology, the company aims to create off-the-shelf antibody therapies capable of addressing COVID-19 and potential future outbreaks. Enzolytics collaborates with contract research organizations and academic institutions across North America and Europe to advance its research and development pipeline.
Enzolytics operates primarily within the United States and has established strategic alliances and licensing arrangements to support international expansion. Its leadership team comprises professionals with extensive experience in virology, immunology, and pharmaceutical development, guiding the company through preclinical programs and early-stage clinical trials. The company maintains research facilities that underpin its efforts to translate scientific discoveries into viable therapeutic candidates.
Looking ahead, Enzolytics is pursuing partnerships to expand manufacturing capacity and accelerate clinical development. By leveraging its proprietary platforms, the company seeks to streamline production processes for both peptide-based vaccines and monoclonal antibodies. Planned clinical investigations and collaborative agreements are intended to support future regulatory engagements and potential commercialization strategies.
AI Generated. May Contain Errors.
